COVID-19 associated mucormycosis, host-iron assimilation: Probiotics can be a novel therapy.

Bhardwaj, Ankit; Roy, Vandana

Bhardwaj, Ankit; Roy, Vandana.

Bhardwaj A; Department of Pharmacology, ABVIMS and Dr. RML Hospital, New Delhi, India.
Roy V; Department of Pharmacology, MAMC and LNJP Hospital, New Delhi, India.

Indian J Pharmacol ; 53(5): 415-416, 2021.

Article in English | MEDLINE | ID: covidwho-1547556

Subject(s)

COVID-19/complications; Iron/blood; Mucorales/pathogenicity; Mucormycosis/therapy; Probiotics/therapeutic use; Animals; COVID-19/blood; COVID-19/immunology; COVID-19/virology; Host-Pathogen Interactions; Humans; Iron Chelating Agents/therapeutic use; Mucorales/immunology; Mucorales/metabolism; Mucormycosis/blood; Mucormycosis/immunology; Mucormycosis/microbiology; Probiotics/adverse effects; SARS-CoV-2/immunology; SARS-CoV-2/pathogenicity; Virulence

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Probiotics / COVID-19 / Iron / Mucorales / Mucormycosis Topics: Long Covid Limits: Animals / Humans Language: English Journal: Indian J Pharmacol Year: 2021 Document Type: Article Affiliation country: Ijp.ijp_406_21

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google